Study guide

9.1 Acute Stroke, TIA, & Neurovascular Emergencies

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

9.1 Acute Stroke, TIA, & Neurovascular Emergencies

Key Takeaways Explain This Topic AI

Immediate non-contrast head CT is the essential first-line imaging modality to differentiate ischemic from hemorrhagic stroke prior to initiating any acute thrombolytic therapy.

According to Canadian Stroke Best Practice Recommendations, IV tenecteplase or alteplase is indicated within 4.5 hours of clear symptom onset provided blood pressure is controlled <185/110 mmHg and no contraindications exist.

Endovascular thrombectomy (EVT) is standard of care for anterior circulation large vessel occlusion within 6 hours, and up to 24 hours in selected patients demonstrating a favorable CT perfusion mismatch.

High-risk TIA (ABCD2 score ≥ 4, motor weakness, or speech deficit) requires urgent evaluation within 24 hours, CTA head/neck, and short-term dual antiplatelet therapy (aspirin plus clopidogrel for 21–90 days).

A normal non-contrast head CT within 6 hours of thunderclap headache onset has high sensitivity for subarachnoid hemorrhage, but lumbar puncture for CSF xanthochromia remains mandatory if clinical suspicion is high and CT is negative.

Last updated: July 2026

Introduction & Hyperacute Assessment

Acute neurovascular events are medical emergencies where rapid recognition, imaging, and intervention directly dictate long-term functional recovery. In Canada, stroke is a leading cause of adult disability and mortality. The clinical approach to acute neurovascular disease centers on rapid differentiation between ischemic stroke, hemorrhagic stroke, and stroke mimics, followed by time-critical reperfusion therapies.

Initial Triage & Emergency Workup

Upon presentation with hyperacute neurological deficits (onset of focal weakness, facial drooping, speech disturbance, or sensory loss):

Stabilize Airway, Breathing, and Circulation (ABCs): Ensure adequate oxygenation ( S p O 2 ≥ 94 % SpO_2 \ge 94\% Sp O 2 ​ ≥ 94% ) and continuous cardiac monitoring.

Check Capillary Blood Glucose Immediately: Hypoglycemia ( < 2.8 mmol/L <2.8\text{ mmol/L} < 2.8 mmol/L ) is the most critical and easily reversible stroke mimic. Severe hyperglycemia can also exacerbate ischemic brain injury.

Perform Focused Neurological Assessment: Calculate the National Institutes of Health Stroke Scale (NIHSS) score to quantify stroke severity and establish baseline function.

STAT Non-Contrast Computed Tomography (NCCT) Head: NCCT must be performed immediately. The primary objective of hyperacute NCCT is not to visualize early ischemic changes, but to rule out intracranial hemorrhage (ICH) prior to initiating antiplatelet or thrombolytic therapy.

Computed Tomography Angiography (CTA): CTA of the head and neck (from aortic arch to vertex) should be performed concurrently with NCCT in all acute stroke candidates to detect Large Vessel Occlusions (LVO) eligible for Endovascular Thrombectomy (EVT).

Ischemic Stroke Thrombolysis & Endovascular Thrombectomy

Ischemic stroke accounts for approximately 85% of all stroke presentations, resulting from thromboembolic arterial occlusion. Canadian Stroke Best Practice Recommendations (CSBPR) emphasize rapid door-to-needle (DTN target < 30 minutes <30\text{ minutes} < 30 minutes ) and door-to-groin-puncture times.

Intravenous Thrombolysis

Intravenous thrombolysis degrades fibrin clots by activating plasminogen to plasmin. CSBPR recommends Tenecteplase (TNK) 0.25 mg/kg 0.25\text{ mg/kg} 0.25 mg/kg IV single bolus (maximum 25 mg 25\text{ mg} 25 mg ) or Alteplase (tPA) 0.9 mg/kg 0.9\text{ mg/kg} 0.9 mg/kg IV (10% bolus, 90% infusion over 60 minutes, maximum 90 mg 90\text{ mg} 90 mg ). Tenecteplase is increasingly preferred in Canadian stroke centers due to rapid single-bolus administration and superior fibrin specificity.

  • Thrombolysis Parameter Canadian Best Practice Guidelines
  • Eligible Time Window Within 4.5 hours of clear symptom onset (or last known well time)

Pre-Administration BP Target Systolic BP < 185 mmHg <185\text{ mmHg} < 185 mmHg and Diastolic BP < 110 mmHg <110\text{ mmHg} < 110 mmHg

Post-Administration BP Target Maintain BP < 180 / 105 mmHg <180/105\text{ mmHg} < 180/105 mmHg for at least 24 hours post-thrombolysis

Antiplatelet / Anticoagulant Hold Hold aspirin, heparin, or clopidogrel for 24 hours post-thrombolysis until follow-up CT rules out hemorrhagic transformation

Absolute Contraindications to Intravenous Thrombolysis

Active internal bleeding or acute bleeding diathesis.

Prior intracranial hemorrhage (ICH) at any time.

Known intracranial neoplasm, arteriovenous malformation (AVM), or aneurysm.

Severe head trauma or intracranial/intraspinal surgery within the preceding 3 months.

Uncontrolled severe hypertension (SBP > 185 mmHg >185\text{ mmHg} > 185 mmHg or DBP > 110 mmHg >110\text{ mmHg} > 110 mmHg unresponsive to acute IV antihypertensive therapy).

Platelet count < 100 × 10 9 /L <100 \times 10^9\text{/L} < 100 × 1 0 9 /L , INR > 1.7 >1.7 > 1.7 , or elevated aPTT.

Direct Oral Anticoagulant (DOAC) ingestion within the last 48 hours (unless specific lab assays show no anticoagulant activity or specific reversal agent available).

Endovascular Thrombectomy (EVT)

EVT involves mechanical intra-arterial clot retrieval using stent retrievers or aspiration catheters. It provides dramatic functional benefits for large vessel occlusions.

Indications: Occlusion of the internal carotid artery (ICA) or proximal middle cerebral artery (MCA M1/M2 segment), pre-stroke modified Rankin Scale (mRS) score 0–1, age ≥ 18 \ge 18 ≥ 18 , and NIHSS ≥ 6 \ge 6 ≥ 6 .

Standard Time Window: Within 6 hours of symptom onset.

Extended Time Window (6 to 24 Hours): Select patients presenting between 6 and 24 hours after last known well (including wake-up strokes) are eligible for EVT if CT Perfusion (CTP) or diffusion-weighted MRI demonstrates a small ischemic core with a large salvageable ischemic penumbra (DAWN and DEFUSE-3 trial criteria).

Exam Trap: Do NOT delay EVT administration while waiting to observe clinical response to IV thrombolysis. If a patient is eligible for both IV thrombolysis and EVT, initiate IV tenecteplase/alteplase immediately and simultaneously dispatch the patient to the angiography suite for EVT ("bridge therapy").

Permissive Hypertension & BP Management in Acute Stroke

Blood pressure management in hyperacute ischemic stroke requires balancing perfusion of the ischemic penumbra against the risk of cerebral edema or hemorrhagic transformation.

Management Rules

Patients Eligible for IV Thrombolysis / EVT: Lower BP to < 185 / 110 mmHg <185/110\text{ mmHg} < 185/110 mmHg prior to bolus using short-acting IV agents (Labetalol 10 – 20 mg 10\text{--}20\text{ mg} 10 – 20 mg IV, Nicardipine infusion, or Hydralazine). Maintain < 180 / 105 mmHg <180/105\text{ mmHg} < 180/105 mmHg for 24 hours.

Patients NOT Eligible for Thrombolysis / EVT: Allow permissive hypertension up to 220 / 120 mmHg 220/120\text{ mmHg} 220/120 mmHg for the first 24 to 48 hours. Do not lower blood pressure unless SBP > 220 mmHg >220\text{ mmHg} > 220 mmHg or DBP > 120 mmHg >120\text{ mmHg} > 120 mmHg , or if acute concomitant end-organ damage is present (e.g., acute aortic dissection, acute myocardial infarction, acute pulmonary edema, or hypertensive encephalopathy). When lowering is required, reduce mean arterial pressure (MAP) by no more than 15% in the first 24 hours.

TIA & Secondary Stroke Prevention

A Transient Ischemic Attack (TIA) is defined as a brief episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction on tissue imaging (neuroimaging negative). TIA represents an urgent warning sign; up to 10% of TIA patients suffer an ischemic stroke within 90 days, with the highest risk occurring in the first 48 hours.

  • ABCD2 Risk Stratification Score
  • A ge ≥ 60 \ge 60 ≥ 60 years (1 point)
  • B lood Pressure ≥ 140 / 90 mmHg \ge 140/90\text{ mmHg} ≥ 140/90 mmHg at initial evaluation (1 point)
  • C linical Features: Unilateral motor weakness (2 points), Speech impairment without weakness (1 point)
  • D uration of Symptoms: ≥ 60 \ge 60 ≥ 60 minutes (2 points), 10 – 59 10\text{--}59 10 – 59 minutes (1 point)
  • D iabetes Mellitus history (1 point)

Patients with high-risk TIA (ABCD2 score ≥ 4 \ge 4 ≥ 4 , motor weakness, speech deficit, or fluctuating symptoms) require immediate workup within 24 hours at a rapid-access TIA clinic or emergency department.

Acute Secondary Prevention Protocols

Dual Antiplatelet Therapy (DAPT): For non-cardioembolic high-risk TIA or minor ischemic stroke (NIHSS ≤ 3 \le 3 ≤ 3 ), initiate Aspirin 81 mg 81\text{ mg} 81 mg + Clopidogrel 75 mg 75\text{ mg} 75 mg daily (following loading doses of Aspirin 160 – 325 mg 160\text{--}325\text{ mg} 160 – 325 mg and Clopidogrel 300 – 600 mg 300\text{--}600\text{ mg} 300 – 600 mg ) for 21 to 90 days (based on CHANCE and POINT trials), followed by monotherapy (Clopidogrel or Aspirin). DAPT beyond 90 days increases bleeding risk without incremental benefit.

High-Intensity Statin: Initiate Atorvastatin 80 mg 80\text{ mg} 80 mg daily immediately regardless of baseline LDL-C.

Vascular Imaging: Perform urgent CTA or carotid Doppler ultrasound. If symptomatic carotid artery stenosis is 70 % – 99 % 70\%\text{--}99\% 70% – 99% , perform Carotid Endarterectomy (CEA) within 14 days of the index event.

Cardioembolic Workup: Holter monitoring to detect occult Atrial Fibrillation. If atrial fibrillation is identified, initiate Direct Oral Anticoagulant (DOAC: Apixaban, Rivaroxaban, Dabigatran, or Edoxaban) therapy. Delay initiation by 3 to 14 days post-stroke depending on stroke size and hemorrhagic risk.

  • Hemorrhagic Neurovascular Emergencies
  • Intracerebral Hemorrhage (ICH)

Intracerebral hemorrhage results from rupture of small penetrating arteries damaged by chronic hypertension (Charcot-Bouchard microaneurysms) or amyloid angiopathy.

Clinical Presentation: Sudden focal neurological deficit accompanied by headache, vomiting, rapid elevation of BP, and declining level of consciousness.

Acute Interventions:

BP Reduction: Rapidly lower SBP to a target of 130 – 140 mmHg 130\text{--}140\text{ mmHg} 130 – 140 mmHg using IV labetalol or nicardipine (avoiding SBP < 110 mmHg <110\text{ mmHg} < 110 mmHg ).

Anticoagulation Reversal:

Warfarin: IV Vitamin K 10 mg 10\text{ mg} 10 mg + 4-factor Prothrombin Complex Concentrate (PCC).

Dabigatran: Idarucizumab 5 g 5\text{ g} 5 g IV.

Factor Xa Inhibitors (Apixaban/Rivaroxaban): Andexanet alfa or 4-factor PCC ( 50 units/kg 50\text{ units/kg} 50 units/kg ).

Heparin: Protamine sulfate.

Neurosurgical Consultation: Indicated for cerebellar hemorrhage > 3 cm >3\text{ cm} > 3 cm with neurological deterioration, brainstem compression, or hydrocephalus.

Subarachnoid Hemorrhage (SAH)

Subarachnoid hemorrhage is most commonly caused by rupture of a saccular ("berry") aneurysm in the Circle of Willis (most frequent site: Anterior Communicating Artery).

Clinical Features: Sudden, catastrophic "thunderclap" headache ("worst headache of my life"), reaching peak intensity within seconds, accompanied by vomiting, meningismus (nuchal rigidity, Kernig/Brudzinski signs), photophobia, and transient loss of consciousness.

Diagnostic Algorithm:

Non-Contrast Head CT: Highly sensitive ( > 95 % >95\% > 95% ) within the first 6 hours of headache onset.

Lumbar Puncture (LP): If NCCT is negative or equivocal and clinical suspicion remains high, LP is mandatory . Inspect CSF for xanthochromia (yellowish discoloration of CSF supernatant caused by bilirubin from RBC breakdown), which requires 12 hours from headache onset to reliably develop. Spectrophotometry or centrifuge visual inspection confirms SAH.

Cerebral Angiography (CTA or Digital Subtraction Angiography): Performed to identify the ruptured aneurysm.

Complications & Management:

Vasospasm Prevention: Oral Nimodipine 60 mg 60\text{ mg} 60 mg q4h for 21 days improves neurological outcomes by preventing delayed cerebral ischemia.

Aneurysm Repair: Endovascular coiling or surgical clipping within 24–72 hours to prevent rebleeding.

Hydrocephalus: Managed with External Ventricular Drain (EVD).

Clinical Scenario: A 48-year-old female presents to the ED with a severe, instantaneous headache that began 8 hours ago. Her non-contrast CT head is completely normal. The candidate must recognize that a normal CT at 8 hours DOES NOT rule out subarachnoid hemorrhage. The mandatory next step is a lumbar puncture to assess for xanthochromia.

Loading diagram... Acute Ischemic Stroke & TIA Diagnostic and Treatment Pathway